Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Changchun High-tech: Subsidiary's application for registration clinical trial of domestically produced drug GenSci136 has been accepted
Changchun High and New Technology Industry announced that its controlling subsidiary, Jinsai Pharmaceutical, has received acceptance from the National Medical Products Administration for its domestic manufacturing registration clinical trial application for GenSci136 for injection.
GenSci136 for injection is a Class 1 biologic therapeutic for treatment independently developed by Jinsai Pharmaceutical, and is intended for the treatment of ocular myasthenia gravis (oMG).
Previously, clinical trial applications for this drug for the treatment of generalized myasthenia gravis (gMG) and immunoglobulin A nephropathy (IgAN) had also been accepted and approved.